•
China-based high-value medical device firm Mingche Biotechnology (Suzhou) Co., Ltd has reportedly raised “tens of millions” of renminbi in a pre-Series A financing round. This significant capital raise was led by Suzhou Industrial Park Development Zhidao Equity Investment Partnership and Qianrong Capital, with additional contributions from Haida Investment. The funds…
•
Hangzhou Dessight Biomedical has reportedly raised “tens of millions” of renminbi in a Pre-Series A financing round. This significant capital injection was led by Linear Venture, with GL Ventures also participating. The funds will be directed towards market filing for an ophthalmic surgery robot, the development of microsurgery robots, and…
•
China-based Luye Pharma Group (HKG: 2186) has announced the first subject dosing in a Phase I clinical study for its BA1106, an in-house developed CD25 monoclonal antibody (mAb). The study, filed by subsidiary Shandong BoAn Biotechnology Co., Ltd, is designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of…
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that a clinical trial filing for its ZGGS15, a bispecific antibody (BsAb) targeting LAG-3 and TIGIT in advanced solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone as ZGGS15 is touted…
•
China-based Kintor Pharmaceutical Ltd (HKG: 9939) has announced positive topline data from a Phase I clinical study in the United States for its GT20029, a treatment for androgenetic alopecia (AGA) and acne. This marks a significant step in the development of a novel treatment option for these common conditions. Phase…
•
China’s Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced that its SHR-A1811, an HER2 targeted antibody-drug conjugate (ADC), is on course to obtain breakthrough therapy designation (BTD) status from the Center for Drug Evaluation (CDE) in China. This designation is for the treatment of unresectable or metastatic breast cancer with low…
•
EOC Pharma, a biotech operating out of the US and China, has announced that a clinical trial filing for its CDK7 inhibitor EOC237 has been accepted for review by the Center for Drug Evaluation (CDE) in China. This marks a significant milestone in the development of EOC237, which is expected…
•
China-based Joincare Pharmaceutical Industry Group Co., Ltd (SHA: 600380) has announced that the market filing for its generic version of GlaxoSmithKline’s (GSK, NYSE: GSK) Seretide (salmeterol, fluticasone) has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant milestone for Joincare, which holds the first-mover…
•
Nona Biosciences, a wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck a partnership with US firm Mythic Therapeutics. The collaboration aims to leverage Nona’s HCAb transgenic mice platform technology and antibody discovery services to develop next-generation antibody-drug conjugates (ADCs) targeting multiple tumors. No financial details were disclosed. Partnership…
•
China-based Everest Medicines (HKG: 1952) has announced that South Korea’s Ministry of Food and Drug Safety (MFDS) has included the firm’s Nefecon (targeted-release formulation-budesonide) in the Global Innovative Fast Track (GIFT) program for the treatment of primary immunoglobulin A nephropathy (IgAN). This designation is a significant step in the development…
•
China-based Shanghai Haohai Biological Technology Co. Ltd (HKG: 6826), a leading biomaterial firm focused on ophthalmology, medical aesthetics, wound care, orthopedics, and anti-adhesion and hemostasis, has announced the acquisition of a 20% stake in compatriot firm Shenzhen New Industries Material of Ophthalmology Co., Ltd (SZNIMO) for a consideration of RMB…
•
China-based biopharma Hinova Pharmaceuticals (SHA: 688302) has announced that a clinical trial filing for its HP530S, a highly active and selective focal adhesion kinase (FAK) inhibitor against solid tumors, has been accepted for review by the National Medical Products Administration (NMPA). This marks a significant step in the development of…
•
UK-based multinational AstraZeneca Plc (AZ, NASDAQ: AZN) has released its financial results for the Q4 and full-year 2022 periods. The firm continues to expand at a rapid pace, with total global revenues up 25% year-on-year (YOY) to USD 44.35 billion. This growth is a testament to AstraZeneca’s strong pipeline and…
•
The Center for Drug Evaluation (CDE) website indicates that China-based Qilu Pharmaceutical’s Category 1 chemical drug candidate QLS12004 has obtained tacit clinical trial approval. This marks a significant step forward in the development of new treatments for solid tumors, including advanced breast cancer, which is the leading malignant cancer affecting…
•
Sino Biopharmaceutical Ltd (HKG: 1177) has announced the decision to terminate the pre-listing process for a previously planned initial public offering (IPO) to the Shanghai Stock Exchange’s Sci-Tech Innovation Board (STAR). This decision comes amidst considerations of the current market situation and corporate development planning. Reasons for TerminationSino Bio cited…
•
China’s Shanghai Pinnacles Medical Technology Co., Ltd has struck a partnership with Japan-based Sysmex Corporation, leveraging their respective advantages and integrating resources to comprehensively cooperate in the area of biochemical immune diagnosis overall solutions. This strategic collaboration aims to enhance the market presence of both companies in the diagnostic sector.…
•
Nanjing-based GenScript ProBio, a leading biologics Contract Development and Manufacturing Organization (CDMO), has formed a long-term partnership with UK-based Bio Immunitas, a firm built around a proprietary human Recombinant Protein Platform (hRPP). This strategic collaboration aims to accelerate Bio Immunitas’s manufacturing capabilities from the lab to clinic, including IND-enabling CMC…
•
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011 IT, has produced positive signs of efficacy as a treatment for melanoma in late-stage patients who have failed previous immunotherapy. In a Phase II clinical study conducted in China and the United States, monotherapy treatment…
•
China-based Ganzhou Hemay Pharmaceutical Co., Ltd, an innovative drug developer focused on autoimmune diseases and oncology, has announced the completion of a Series D financing round at close to RMB 300 million (USD 44.18 million). This significant funding round was led by Hongfu Investment, with contributions from Jihan Capital, Hainan…
•
Neurodawn Pharmaceutical Co., Ltd, a central nervous system (CNS) drug developer based in Nanjing, has announced the completion of a Series A+ financing round in excess of RMB 100 million (USD 14.73 million). The round was led by China Merchants Health, with existing investor Simcere Pharmaceutical Group (HKG: 2096) participating.…